In addition, IDH-C35 can also reduce the level of PD-L1 DNA methylation, increase the expression of PD-L1 on mIDH1 glioma cells in vivo, reshape the tumor microenvironment, and improve the effect of PD-L1 immunotherapy (87). The gene discussed is IDH2; the disease is central nervous system cancer.